Letter: Spasmocanulase in functional bowel disorder, and the importance of pretrial assessment in evaluation of side-effects.
D002482:Cellulose / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003109:Colonic Diseases, Functional / Q000188:drug therapy*; D003685:Dehydrocholic Acid / Q000009:adverse effects; D004129:Dimethylpolysiloxanes; D004338:Drug Combinations; D005971:Glutamates / Q000009:adverse effects; D006801:Humans; D010194:Pancreatin / Q000009:adverse effects; D010276:Parasympatholytics / Q000009:adverse effects*; D010434:Pepsin A / Q000009:adverse effects; D011446:Prospective Studies; D013892:Thioxanthenes / Q000009:adverse effects
D004129:Dimethylpolysiloxanes; D004338:Drug Combinations; D005971:Glutamates; D010276:Parasympatholytics; D013892:Thioxanthenes; C009300:spasmocanulase; D010194:Pancreatin; D002482:Cellulose; D010434:Pepsin A; D003685:Dehydrocholic Acid